Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the Company was recently invited by one of Great Britain’s leading chains [...]
A study conducted by Emotra’s Chief of Research and the inventor of EDOR®, Lars-Håkan Thorell, and the biostatistician Karl Wahlin demonstrates how strongly the company’s test identifies patients at risk of committing suicide. 180904- Emotra - PM - New publication demonstrates the strength of EDOR tests
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2018. 180822 Interim report Jan-June 2018
As we have previously announced, Japan is one of Emotra’s high-priority markets. The company has applied for patents in the EU, USA, Canada and Japan. The Japanese patent office has now informed us that Emotra’s Japanese patent application number 2016-516080 has been approved. 180730- Emotra - PM - Patent approved in Japan
As we notified in a previous newsletter and our annual report, Emotra has changed its market introduction strategy for EDOR®. In the first and second quarter of 2018, we have been working the markets more directly and with a greater geographical focus. Given the company’s resources and previous experience, we have chosen to focus our [...]
The Annual General Meeting of EMOTRA AB (publ) was held today, May 9, 2018. The resolutions, summarised below, were all adopted with the necessary majority. 180509 - Emotra- PM - Communiqué AGM
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first quarter 2018. Summary of the period January – March, 2018 180509- Interim report Jan-Mars 2018
Emotra AB (“Emotra”) hereby announces that an agreement has been reached with a group of researchers at the faculty of medicine at the University of Warsaw. The agreement concerns financial compensation for EDOR® tests in a clinical study. The study in question is a continuation of a research project that was started in connection with [...]
Emotra AB (publ) (“Emotra”) today announces that the Company’s Annual Report for the financial year 2017, as well as other documents required for the Annual General Meeting are available from the Company’s web site (www.emotra.se) as of today, and are also provided upon request by the Company (see address below). 180418 - Emotra- PM - [...]
Notice is hereby given that the Annual General Meeting of shareholders in Emotra AB (publ), 556612-1579, will be held at 11:00 am on Wednesday May 9, 2018, at the restaurant John Scott´s Pub at 15, Kungsportsavenyn in Göteborg. 180409 - Emotra- PM - Notice AGM